<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02086331</url>
  </required_header>
  <id_info>
    <org_study_id>13/LO/0943</org_study_id>
    <secondary_id>13HH0684</secondary_id>
    <nct_id>NCT02086331</nct_id>
  </id_info>
  <brief_title>Evaluation of Musculoskeletal Microcirculation With Ultrasound</brief_title>
  <acronym>EMMU</acronym>
  <official_title>Evaluation of Musculoskeletal Microcirculation With Ultrasound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to validate the use of Dynamic Contrast-Enhanced Ultrasound in measuring the&#xD;
      blood supply to the muscles of the leg, and how this changes with exercise and vascular&#xD;
      pathology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose a model for the use of Dynamic Contrast-Enhanced Ultrasound (DCEU) to directly&#xD;
      evaluate the microcirculation of the musculoskeletal system. We believe that this will be a&#xD;
      valuable research tool into diseases of the microcirculation, and in the future may also&#xD;
      offer a clinical benefit by quantifying and monitoring disease over time and after&#xD;
      intervention. It may also allow targeting of therapies towards those patients most at risk of&#xD;
      ulcers and peripheral neuropathy, and those that would get the maximum benefit from these&#xD;
      therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Threshold of High to Low Frequency Ratio (Threshold HLFR)</measure>
    <time_frame>Baseline, 20 minutes</time_frame>
    <description>Please see published article for in depth method. This ratio is used to classify a given signal as either microbubble or noise. For a pixel containing a micro vessel, as microbubbles occasionally pass this otherwise dark pixel, its temporal signal is expected to have a higher proportion of lower frequency components than white noise. Consequently, the HLFR of the pixel is expected to be smaller than that of noise. A histogram of normalised HLFR shows two expected peaks (one noise, one bubbles). A threshold (Threshold HLFR) is determined to then separate the two peaks. this is done using a double Gaussian model, and where they intercept is deemed the Threshold HLFR.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Standardised Claudication Treadmill Test</condition>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy volunteers, deemed to have normal metabolic and cardiovascular biology by trial criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symptomatic peripheral arterial disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symptomatic diabetic peripheral neuropathy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Contrast enhanced ultrasound</intervention_name>
    <description>Infusion of microbubbles to enhance blood vessels in the leg for ultrasound</description>
    <arm_group_label>DM</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>PAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Treadmill test</intervention_name>
    <description>Exposes you to exercise in a controlled environment. We will see if we can detect this change with our new ultrasound protocol</description>
    <arm_group_label>DM</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>PAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Contrast enhanced ultrasound</intervention_name>
    <arm_group_label>DM</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>PAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Group 1 - Healthy subjects Inclusion&#xD;
&#xD;
          -  18+ years old&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  Personal history of diabetes or peripheral arterial disease, current pregnancy,&#xD;
             previous surgery to the lower limb, heart attack within 4 weeks, or unstable angina&#xD;
&#xD;
        Group 2 - Peripheral arterial disease subjects Inclusion&#xD;
&#xD;
          -  18+ years old, radiological evidence of peripheral arterial disease (arterial doppler&#xD;
             or angiogram), ankle-brachial pressure index (ABPI) 0.5-0.8&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  Personal history of diabetes, current pregnancy, previous amputation, heart attack&#xD;
             within 4 weeks, or unstable angina&#xD;
&#xD;
        Group 3 - Diabetic subjects Inclusion&#xD;
&#xD;
          -  18+ years old, with a clinical diagnoses of diabetes (1, 2)&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
        - ABPI&lt;0.9, previous amputation, current pregnancy or breastfeeding, heart attack within 4&#xD;
        weeks, or unstable angina.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof AH Davies</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>March 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <results_first_submitted>October 5, 2020</results_first_submitted>
  <results_first_submitted_qc>November 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 25, 2020</results_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treadmill test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study was terminated early after the proof of concept stage. We showed that our methodology worked in healthy subjects, then ran out of time thus no participants were enrolled in either the &quot;Symptomatic peripheral arterial disease&quot; or &quot;Symptomatic diabetic peripheral neuropathy&quot; arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy</title>
          <description>Healthy participants</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Poor recruitment. Trial closed early after 5 healthy recruits completed protocol.</population>
      <group_list>
        <group group_id="B1">
          <title>Healthy Subjects</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" lower_limit="21" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Threshold of High to Low Frequency Ratio (Threshold HLFR)</title>
        <description>Please see published article for in depth method. This ratio is used to classify a given signal as either microbubble or noise. For a pixel containing a micro vessel, as microbubbles occasionally pass this otherwise dark pixel, its temporal signal is expected to have a higher proportion of lower frequency components than white noise. Consequently, the HLFR of the pixel is expected to be smaller than that of noise. A histogram of normalised HLFR shows two expected peaks (one noise, one bubbles). A threshold (Threshold HLFR) is determined to then separate the two peaks. this is done using a double Gaussian model, and where they intercept is deemed the Threshold HLFR.</description>
        <time_frame>Baseline, 20 minutes</time_frame>
        <population>5 recruits imaged and analysed. One recruit of five was excluded due to acquisition error</population>
        <group_list>
          <group group_id="O1">
            <title>Subject 1</title>
          </group>
          <group group_id="O2">
            <title>Subject 2</title>
          </group>
          <group group_id="O3">
            <title>Subject 3</title>
          </group>
          <group group_id="O4">
            <title>Subject 4</title>
          </group>
        </group_list>
        <measure>
          <title>Threshold of High to Low Frequency Ratio (Threshold HLFR)</title>
          <description>Please see published article for in depth method. This ratio is used to classify a given signal as either microbubble or noise. For a pixel containing a micro vessel, as microbubbles occasionally pass this otherwise dark pixel, its temporal signal is expected to have a higher proportion of lower frequency components than white noise. Consequently, the HLFR of the pixel is expected to be smaller than that of noise. A histogram of normalised HLFR shows two expected peaks (one noise, one bubbles). A threshold (Threshold HLFR) is determined to then separate the two peaks. this is done using a double Gaussian model, and where they intercept is deemed the Threshold HLFR.</description>
          <population>5 recruits imaged and analysed. One recruit of five was excluded due to acquisition error</population>
          <units>Threshold ratio (no units)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12"/>
                    <measurement group_id="O2" value="0.093"/>
                    <measurement group_id="O3" value="0.16"/>
                    <measurement group_id="O4" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After treadmill protocol, 20mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.167"/>
                    <measurement group_id="O2" value="0.14"/>
                    <measurement group_id="O3" value="0.15"/>
                    <measurement group_id="O4" value="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>Intraclass correlation of repeated measures - 0.96, p=0.08</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Average Percentage Change in Microbubble Track Density Measure (MTD)</title>
        <description>The number of pixels identified as having bubble signals was normalised by dividing by area of region of interest (ROI).&#xD;
MTD = pixels with microbubbles / area of ROI Used as a surrogate for active vascular density. The percentage change between rest and exercise (20 minute treadmill protocol) was calculated on each day</description>
        <time_frame>Test repeated on consecutive day to measure repeatability</time_frame>
        <population>One subject out of five excluded for acquisition error</population>
        <group_list>
          <group group_id="O1">
            <title>Day 1</title>
          </group>
          <group group_id="O2">
            <title>Day 2</title>
          </group>
        </group_list>
        <measure>
          <title>Average Percentage Change in Microbubble Track Density Measure (MTD)</title>
          <description>The number of pixels identified as having bubble signals was normalised by dividing by area of region of interest (ROI).&#xD;
MTD = pixels with microbubbles / area of ROI Used as a surrogate for active vascular density. The percentage change between rest and exercise (20 minute treadmill protocol) was calculated on each day</description>
          <population>One subject out of five excluded for acquisition error</population>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.2" spread="79.8"/>
                    <measurement group_id="O2" value="119.4" spread="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Subject 1</title>
        </group>
        <group group_id="E2">
          <title>Subject 2</title>
        </group>
        <group group_id="E3">
          <title>Subject 3</title>
        </group>
        <group group_id="E4">
          <title>Subject 4</title>
        </group>
        <group group_id="E5">
          <title>Subject 5</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Miss Kate Williams</name_or_title>
      <organization>Imperial College London</organization>
      <email>k.williams@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

